DocGuide -- The use of once-daily, prolonged-release tacrolimus in both conversion (kidney and heart transplant) and de novo transplant (liver and kidney) recipients was found to be safe and well tolerated, with patient and graft survival rates in excess of 90% during a 5-year follow-up period, researchers said here August 17 at the 23rd International Congress of the Transplant Society (ICTS).
